Bicycle Therapeutics Beheer
Beheer criteriumcontroles 4/4
De CEO Bicycle Therapeutics is Kevin Lee, benoemd in Sep2015, heeft een ambtstermijn van 9.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 5.54M, bestaande uit 12.8% salaris en 87.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.37% van de aandelen van het bedrijf, ter waarde $ 5.81M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 5.3 jaar.
Belangrijke informatie
Kevin Lee
Algemeen directeur
US$5.5m
Totale compensatie
| Percentage CEO-salaris | 12.8% |
| Dienstverband CEO | 9.2yrs |
| Eigendom CEO | 0.4% |
| Management gemiddelde ambtstermijn | 2.8yrs |
| Gemiddelde ambtstermijn bestuur | 5.3yrs |
Recente managementupdates
Recent updates
Bicycle Therapeutics plc (NASDAQ:BCYC) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Nov 03
Bicycle Therapeutics (NASDAQ:BCYC) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Oct 23Bicycle Therapeutics Is Looking Increasingly Attractive
Aug 20Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert
May 24Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why
May 10Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher
May 04Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?
Apr 19Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point
Mar 12Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely
Jan 04Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts
Nov 07The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts
May 14Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%
Mar 31Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?
Mar 09Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook
Nov 08Bicycle Therapeutics: Exploring An Intriguing Developmental Platform
Oct 08Bicycle Therapeutics initiated Outperform at Cowen citing drug platform
Aug 31Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration
Jul 12Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?
Jul 10Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer
Jul 05Bicycle Therapeutics: Trying To Catch This Falling Knife
Apr 17Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Apr 11Bicycle Therapeutics: A Buy Ahead Of AACR Presentation
Mar 25Bicycle Therapeutics: An Oncology Play With Big Potential
Feb 28Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?
Nov 07Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles
Aug 25The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically
Aug 07News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts
May 08Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$166m |
| Jun 30 2024 | n/a | n/a | -US$165m |
| Mar 31 2024 | n/a | n/a | -US$168m |
| Dec 31 2023 | US$6m | US$710k | -US$181m |
| Sep 30 2023 | n/a | n/a | -US$162m |
| Jun 30 2023 | n/a | n/a | -US$140m |
| Mar 31 2023 | n/a | n/a | -US$124m |
| Dec 31 2022 | US$9m | US$673k | -US$113m |
| Sep 30 2022 | n/a | n/a | -US$101m |
| Jun 30 2022 | n/a | n/a | -US$87m |
| Mar 31 2022 | n/a | n/a | -US$78m |
| Dec 31 2021 | US$4m | US$677k | -US$67m |
| Sep 30 2021 | n/a | n/a | -US$66m |
| Jun 30 2021 | n/a | n/a | -US$62m |
| Mar 31 2021 | n/a | n/a | -US$56m |
| Dec 31 2020 | US$3m | US$592k | -US$51m |
| Sep 30 2020 | n/a | n/a | -US$38m |
| Jun 30 2020 | n/a | n/a | -US$37m |
| Mar 31 2020 | n/a | n/a | -US$35m |
| Dec 31 2019 | US$4m | US$517k | -US$31m |
| Sep 30 2019 | n/a | n/a | -US$33m |
| Jun 30 2019 | n/a | n/a | -US$31m |
| Mar 31 2019 | n/a | n/a | -US$26m |
| Dec 31 2018 | US$818k | US$386k | -US$22m |
Compensatie versus markt: De totale vergoeding ($USD 5.54M ) Kevin } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.64M ).
Compensatie versus inkomsten: De vergoeding van Kevin is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Kevin Lee (56 yo)
9.2yrs
Tenure
US$5,540,400
Compensatie
Dr. Kevin Lee, M.B.A., Ph D., has been Chief Executive Officer of Bicycle Therapeutics plc since September 2015. Dr. Lee joined Bicycle Therapeutics from Pfizer where he served as Senior Vice President and...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Executive Director | 9.2yrs | US$5.54m | 0.37% $ 5.8m | |
| Co-Founder & Non-Executive Director | no data | US$477.04k | 0.24% $ 3.7m | |
| Chief Financial Officer | 1.3yrs | US$2.88m | geen gegevens | |
| Chief Development Officer | 1.7yrs | US$2.82m | 0% $ 0 | |
| Scientific Founder | no data | geen gegevens | geen gegevens | |
| Chief Operating Officer | 2.8yrs | US$5.98m | 0.024% $ 380.9k | |
| Senior VP | 1.4yrs | geen gegevens | 0.0037% $ 58.1k | |
| Chief Technology Officer | 2.8yrs | US$3.07m | 0.073% $ 1.1m | |
| Senior Vice President of Investor Relations and Corporate Communications | no data | geen gegevens | geen gegevens | |
| General Counsel | 4.6yrs | geen gegevens | geen gegevens | |
| Head of Clinical and Project Management | 8.5yrs | geen gegevens | geen gegevens | |
| Senior VP of Pre-Clinical Development | 6yrs | geen gegevens | geen gegevens |
2.8yrs
Gemiddelde duur
55.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van BCYC wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Executive Director | 9.2yrs | US$5.54m | 0.37% $ 5.8m | |
| Co-Founder & Non-Executive Director | no data | US$477.04k | 0.24% $ 3.7m | |
| Chairman of Scientific Advisory Board | 6.5yrs | geen gegevens | geen gegevens | |
| Non-Executive Chairman | 5.7yrs | US$1.06m | 0.031% $ 488.2k | |
| Independent Non-Executive Director | 3.7yrs | US$482.29k | 0.016% $ 244.1k | |
| Independent Non-Executive Director | 5.3yrs | US$526.91k | 0.016% $ 244.1k | |
| Member of Scientific Advisory Board | 4.1yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 4.1yrs | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | 5.3yrs | US$495.41k | 0.016% $ 244.1k | |
| Member of Scientific Advisory Board | 6.5yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 4.1yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 4.1yrs | geen gegevens | geen gegevens |
5.3yrs
Gemiddelde duur
64yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van BCYC wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).